Targeted therapies for bone sarcomas

od Heymann, Dominique, Rédini, Françoise
Izdano 2013

Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma

od Redini, Françoise, Heymann, Dominique
Izdano u Front Oncol (2015)

Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment

od Verrecchia, Franck, Rédini, Françoise
Izdano u Front Oncol (2018)

RANKL/RANK/OPG: key therapeutic target in bone oncology

od Ando, Kosei, Mori, Kanji, Rédini, Françoise, Heymann, Dominique
Izdano 2008

TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment

od Picarda, Gaëlle, Trichet, Valérie, Téletchéa, Stéphane, Heymann, Dominique, Rédini, Françoise
Izdano 2011

Mifamurtide for the treatment of nonmetastatic osteosarcoma

od Ando, Kosei, Mori, Kanji, Corradini, Nadège, Redini, Françoise, Heymann, Dominique
Izdano 2011

SHH Signaling Pathway Drives Pediatric Bone Sarcoma Progression

od Lézot, Frédéric, Corre, Isabelle, Morice, Sarah, Rédini, Françoise, Verrecchia, Franck
Izdano u Cells (2020)

The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem

od Corre, Isabelle, Verrecchia, Franck, Crenn, Vincent, Redini, Francoise, Trichet, Valérie
Izdano u Cells (2020)

Antagonistic Functions of Connexin 43 during the Development of Primary or Secondary Bone Tumors

od Talbot, Julie, Dupuy, Maryne, Morice, Sarah, Rédini, Françoise, Verrecchia, Franck
Izdano u Biomolecules (2020)

New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?

od Danieau, Geoffroy, Morice, Sarah, Rédini, Françoise, Verrecchia, Franck, Brounais-Le Royer, Bénédicte
Izdano u Int J Mol Sci (2019)

Hippo/YAP Signaling Pathway: A Promising Therapeutic Target in Bone Paediatric Cancers?

od Morice, Sarah, Danieau, Geoffroy, Rédini, Françoise, Brounais-Le-Royer, Bénédicte, Verrecchia, Franck
Izdano u Cancers (Basel) (2020)

Molecular Alterations Associated with Osteosarcoma Development

od Ando, Kosei, Mori, Kanji, Verrecchia, Franck, Marc, Baud'huin, Rédini, Françoise, Heymann, Dominique
Izdano 2012

Current Therapeutic Strategies and Novel Approaches in Osteosarcoma

od Ando, Kosei, Heymann, Marie-Françoise, Stresing, Verena, Mori, Kanji, Rédini, Françoise, Heymann, Dominique
Izdano 2013

Anticancer activity of halofuginone in a preclinical model of osteosarcoma: inhibition of tumor growth and lung metastases

od Lamora, Audrey, Mullard, Mathilde, Amiaud, Jérôme, Brion, Régis, Heymann, Dominique, Redini, Françoise, Verrecchia, Franck
Izdano u Oncotarget (2015)

TGF-β Signaling in Bone Remodeling and Osteosarcoma Progression

od Lamora, Audrey, Talbot, Julie, Mullard, Mathilde, Brounais-Le Royer, Benedicte, Redini, Françoise, Verrecchia, Franck
Izdano u J Clin Med (2016)

A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis

od Le Goff, Benoit, Soltner, Elise, Charrier, Céline, Maugars, Yves, Rédini, Françoise, Heymann, Dominique, Berthelot, Jean-Marie
Izdano 2009

Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models

od Gobin, Bérengère, Moriceau, Gatien, Ory, Benjamin, Charrier, Céline, Brion, Régis, Blanchard, Frederic, Redini, Françoise, Heymann, Dominique
Izdano 2014

L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer

od Biteau, Kevin, Guiho, Romain, Chatelais, Mathias, Taurelle, Julien, Chesneau, Julie, Corradini, Nadège, Heymann, Dominique, Redini, Françoise
Izdano u Am J Cancer Res (2016)

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma

od Lamoureux, Francois, Baud'huin, Marc, Ory, Benjamin, Guiho, Romain, Zoubeidi, Amina, Gleave, Martin, Heymann, Dominique, Rédini, Françoise
Izdano 2014

Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis

od Grimaud, Eva, Soubigou, Luc, Couillaud, Séverine, Coipeau, Patrick, Moreau, Anne, Passuti, Norbert, Gouin, François, Redini, Françoise, Heymann, Dominique
Izdano 2003